Page 18

“ In many pulmonary diseases there is a paucity of data on

Control (Sham Surgery)

pathophysiology in racial minorities. Our diverse community is helping us fill this gap.” – STEVEN G. KELSEN, MD

Sepsis

Sepsis + PKCδ Inhibitor

ATHEROSCLEROSIS CAUSES HEART DISEASE. WHAT CAUSES PULMONARY DISEASE? Dissecting Mechanisms of Lung Disease Several Temple researchers are investigating inflammatory, immune, or infectious processes in the lung. From biochemistry to epidemiology, Temple scientists are leaders in the worldwide movement to better understand the root causes of lung disease and develop novel treatment approaches.

> Steven G. Kelsen, MD, focuses on chronic obstructive pulmonary disease (chronic

bronchitis and emphysema) and on the impact of specific stressors like cigarette

smoke on alveolar, airway epithelial, and immune cell function. Dr. Kelsen uses

a variety of proteomic, cellular, and molecular techniques to study cells and tissues

obtained from at-risk or diseased individuals. Results are correlated with patient

genotype or phenotype, pharmaceutical treatment, and population factors such as

racial/ethnic background. Dr. Kelsen has two main goals: to determine the cellular

and molecular mechanisms that underpin lung damage and to identify the individual

susceptibility factors that confer lung risk.

> How neutrophils flip from host defender to inflammatory instigator in the lung ABOVE PKC kinases are signaling transducers for diverse biological functions; inhibitors of specific PKC isoforms can regulate inflammatory responses as shown in this animal experiment where a novel PKCδ inhibitor protected against sepsis-induced acute respiratory distress syndrome.

14

HEART | LUNG

—as in acute respiratory distress syndrome—is the question being asked by

Laurie Kilpatrick, PhD. Her laboratory is investigating the signaling pathways that

control neutrophil migration and release of toxic oxygen radicals and proteases.

One such pathway involving Protein Kinase C delta (PKCδ) is now targeted in

preclinical studies with novel PKCδ inhibitors. The goal is to protect the lung

from neutrophil-mediated inflammatory diseases.

Profile for Temple Health

Temple University School of Medicine - Highlights of Basic and Clinical Research - 2014  

Temple University School of Medicine is pushing the boundaries of science to help reduce the devastating effects of heart and lung disease,...

Temple University School of Medicine - Highlights of Basic and Clinical Research - 2014  

Temple University School of Medicine is pushing the boundaries of science to help reduce the devastating effects of heart and lung disease,...